On Demand 2023 Saturday AM General Sessions

This collection covers general sessions from Saturday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Opening Ceremony and Welcome Announcements
  • Presidential Plenary - Trending Topics in Allergy and Immunology
  • Editor's Pick - Best Articles from Annals of Allergy, Asthma and Immunology
  • Is There a Mild Food Allergy Phenotype?
  • Recent Advances in Diagnosis and Monitoring of Respiratory Conditions
  • Physical Urticaria Provocation: Diagnostics and Interpretation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

Upon completion of this session, participants should be able to:

  • Understand the FDA/CBER’s role in food allergen monitoring and the recent decision surrounding food allergen labeling.
  • Discuss the rationale for, and the role of, ICS-SABA in asthma management.
  • Consider potential changes in therapeutic options, future management of anaphylaxis.
  • Identify and manage ‘Mild’ food-allergic patients.
  • Describe new approaches to patient management, such as single, low-dose food challenges.
  • Discuss the use of a food allergy scoring system in development.
  • Review the history and clinical implications of race-based spirometry.
  • Describe how respiratory conditions can be evaluated and managed via telehealth.
  • Discuss when to appropriately treat patients with ICS+SABA and ICS+LABA.
  • Review sleep study findings and CPAP use in OSA.
  • Utilize a detailed clinical history to clarify the cause of cough.
  • Incorporate discussion of biologics and JAK inhibitors into management options for patients with severe atopic dermatitis.
  • Differentiate between spontaneous and inducible urticaria and treatment options.
  • Describe the most common causes of inducible urticaria.
  • Perform various provocation and threshold tests for inducible urticaria.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Course opens: 
Course expires: 

Kathleen R. May, MD, FACAAI
Jay E. Slater, MD
Leonard B. Bacharier, MD, FACAAI
David B.K. Golden, MDCM, FACAAI
David R. Stukus, MD, FACAAI
Mitchell H. Grayson, MD, FACAAI
John J. Oppenheimer, MD, FACAAI
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI
Theresa A. Bingemann, MD, FACAAI
Dixie D. Griffin, MD, FACAAI
David A Khan, MD, FACAAI
Jonathan A. Bernstein, MD, FACAAI
Eric T. Oliver, MD
Aikaterini Anagnostou, MD, PhD, FACAAI
Stephanie A. Leonard, MD
Douglas P. Mack, MD, MSc
Adam Fox, MD, FRCPCH
Marcus S. Shaker, MD, MSc, FACAAI
Jeremy S. Katcher, MD, FACAAI
Zachary W. Marshall, MD
Bridgette L. Jones, MD
Travis A. Miller, MD, FACAAI
Alan P Baptist, MD, FACAAI
Brian David Robertson, MD, FACAAI

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Please login or create an account to take this course.